Allegiance Equity Corporation announces introduction of CinGx capsules -- the first product to target conditions related to recently discovered Type 3 Diabetes

Delivery  systems to include single serve beverage format, tea bags, crystal light beverages and tabletop sweetener packets

TORONTO, September 29, 2012 /CNW/ - Allegiance Equity Corporation (TSXV:ANQ.V) has announced its revolutionary new product that  helps prevent and treat conditions related to newly discovered Type 3 Diabetes and Alzheimer's disease.  CinGx will be available for the first time in a capsule format on line from Collagenna Skin Care Products Inc.

CinGx™, a formula combining extracts acting synergistically to control glucose metabolism, improves cognitive function and simultaneously reduces the risk of developing and treating conditions associated with CVD, diabetes, dementia and Alzheimer’s.   A patented combination of these extracts, CinGx™ has recently received Health Canada approval as well as meeting all FDA requirements for sale and distribution. It has been hailed as a breakthrough for treating Type 3 by members of the scientific community, including Dr. William Klein, Neurobiology Professor at Northwestern University, and Dr. Marcus Cantillon, American Board Certified Neurologist and Psychiatrist.

High blood sugar, a silent insidious condition, attacks the total body, severely impacting cardiovascular and neurological systems. CinGX is effective for treating and preventing high blood glucose, a major factor in diabetes, cardiovascular and neurological conditions including Alzheimer`s and dementia.

It has recently been discovered that the brain produces insulin, and that the lack of insulin and high blood glucose are major factors impacting brain function negatively, thereby increasing the incidence and severity of Alzheimer's and Dementia a condition known as Type 3 Diabetes. Allegiance specifically developed and obtained approval from the International PCT Examiner for the claims that CinGx™ treats  and prevents the conditions associated with Type 3 Diabetes.

"We're intrigued by the claim that insulin receptor protein tyrosine kinase might be stimulated by Allegiance's formulation," says Dr. Klein. “CinGx™ combines two standardized natural extracts, which act synergistically to control glucose metabolism, improve cognitive function, and simultaneously minimize the risk of developing diabetes, dementia and Alzheimer's.”

A new selling website will be up shortly  www.cingx.com and marketing will commence in the next 10 days. CinGx™ meets FDA and all other North American regulatory requirements including those of the FDA.

“We know of no other product available or developed specifically to treat this combination of conditions,” says David Solomon, Allegiance president. “CinGx will soon be available in the battle against the conditions associated with diabetes and memory loss in our unique synergistic formulation.”

CinGx™ can be taken as a nutritional supplement or uniquely delivered in a wide variety of food and beverage products in the single serve beverage format, tea bags, crystal light beverages and tabletop sweetener packets. Nealanders International - a world-class supplier of ingredients and additives in the food industry, is the exclusive distributor of CinGx(TM) in North America.